Trial Review

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT01221623




Registration number
NCT01221623
Ethics application status
Date submitted
8/10/2010
Date registered
15/10/2010
Date last updated
5/10/2017

Titles & IDs
Public title
Study of AA4500 in the Treatment of Peyronie's Disease
Scientific title
A Phase 3, Double-Blind, Randomized, Placebo-Controlled Study of the Safety and Effectiveness of AA4500 Administered Twice Per Treatment Cycle for Up to Four Treatment Cycles (2 x 4) in Men With Peyronie's Disease
Secondary ID [1] 0 0
AUX-CC-804
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Peyronie's Disease 0 0
Condition category
Condition code
Renal and Urogenital 0 0 0 0
Other renal and urogenital disorders

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Other interventions - AA4500
Other interventions - Placebo

Experimental: AA4500 - collagenase clostridium histolyticum

Placebo Comparator: Placebo - Placebo


Other interventions: AA4500
2 injections separated by at least 24 hours but not more than 72 hours. At least 24 hours but not more than 72 hours after the 2nd injection of the treatment cycle, the investigator will model the plaque (ie, gradual, gentle stretching of the flaccid penis in the direction opposite to the curvature). Treatment may be repeated after 42 days (± 5 days) for up to 4 treatment cycles.

Other interventions: Placebo
2 injections separated by at least 24 hours but not more than 72 hours. At least 24 hours but not more than 72 hours after the 2nd injection of the treatment cycle, the investigator will model the plaque (ie, gradual, gentle stretching of the flaccid penis in the direction opposite to the curvature). Treatment may be repeated after 42 days (± 5 days) for up to 4 treatment cycles.
Intervention code [1] 0 0
Other interventions
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Percentage Change From Baseline in Penile Curvature
Timepoint [1] 0 0
Baseline and Week 52
Primary outcome [2] 0 0
Change From Baseline in the Peyronie's Disease Bother Domain of the Peyronie's Disease Questionnaire (PDQ)
Timepoint [2] 0 0
Baseline and Week 52
Secondary outcome [1] 0 0
A Responder Analysis Based on Subject Overall Global Assessment
Timepoint [1] 0 0
Week 52
Secondary outcome [2] 0 0
Change From Baseline in the Severity of Peyronie's Disease Symptoms Domain of the PDQ
Timepoint [2] 0 0
Baseline and Week 52
Secondary outcome [3] 0 0
Change in the Overall Satisfaction Domain of the International Index of Erectile Function (IIEF)
Timepoint [3] 0 0
Baseline and Week 52
Secondary outcome [4] 0 0
Change From Baseline in Penile Plaque Consistency
Timepoint [4] 0 0
Baseline and Week 52
Secondary outcome [5] 0 0
Change From Baseline in Penile Length
Timepoint [5] 0 0
Baseline and Week 52
Secondary outcome [6] 0 0
Change From Baseline in the Penile Pain Domain of the PDQ in Subjects With Baseline Penile Pain Score =4
Timepoint [6] 0 0
Baseline and Week 52
Secondary outcome [7] 0 0
A Composite Responder Analysis Based on Change From Baseline in Penile Curvature and in the Peyronie's Disease Bother Score
Timepoint [7] 0 0
Week 52

Eligibility
Key inclusion criteria
1. Be a male and be = 18 years of age

2. Be in a stable relationship with a female partner/spouse for at least 3 months before
screening and be willing to have vaginal intercourse with that partner/spouse

3. Have symptom(s) of Peyronie's disease for at least 12 months before the first dose of
study drug and have evidence of stable disease as determined by the investigator

4. Have penile curvature of at least 30° in the dorsal, lateral, or dorsal/lateral plane
at screening. It must be possible to delineate the single plane of maximal curvature
for evaluation during the study

5. Be judged to be in good health, based upon the results of a medical history, physical
examination, and laboratory profile

6. Voluntarily sign and date an informed consent agreement approved by the Institutional
Review Board/Independent Ethics Committee (IRB/IEC). The subject must also sign an
authorization form to allow disclosure of his protected health information (PHI). The
PHI authorization form and informed consent form may be an integrated form or may be
separate forms depending on the institution

7. Be able to read, complete, and understand the various rating instruments in English
Minimum age
18 Years
Maximum age
No limit
Sex
Males
Can healthy volunteers participate?
No
Key exclusion criteria
1. Has a penile curvature of less than 30° or greater than 90° at the screening visit

2. Has any of the following conditions:

- Chordee in the presence or absence of hypospadias

- Thrombosis of the dorsal penile artery and/or vein

- Infiltration by a benign or malignant mass resulting in penile curvature

- Infiltration by an infectious agent, such as lymphogranuloma venereum

- Ventral curvature from any cause

- Presence of an active sexually transmitted disease

- Known active hepatitis B or C

- Known immune deficiency disease or be positive for human immunodeficiency virus
(HIV)

3. Has previously undergone surgery for Peyronie's disease

4. Fails to have an erection which in the opinion of the investigator is sufficient to
accurately measure the subject's penile deformity after administration of
prostaglandin E1 (PGE1) or trimix

5. Has a calcified plaque as evident by appropriate radiographic evaluation, penile x-ray
or penile ultrasound that would prevent proper injection of study medication.
Non-contiguous stippling of calcium is acceptable for inclusion provided the calcium
deposit does not interfere with the injection of AA4500 into the plaque

6. Has an isolated hourglass deformity of the penis

7. Has the plaque causing curvature of the penis located proximal to the base of the
penis, so that the injection of the local anesthetic would interfere with the
injection of AA4500 into the plaque

8. Has previously received alternative medical therapies for Peyronie's disease
administered by the intralesional route (including, but not limited to, steroids,
verapamil, and the naturally occurring low molecular weight protein, interferon-a2b)
within 3 months before the first dose of study drug or plans to use any of these
medical therapies at any time during the study

9. Has received alternative medical therapies for Peyronie's disease administered by the
oral (including, but not limited to, vitamin E [> 500 U], potassium aminobenzoate
[Potaba], tamoxifen, colchicine, pentoxifylline, over-the-counter erectile dysfunction
medications, or steroidal anti-inflammatory drugs) or topical routes (including, but
not limited to, verapamil applied as a cream) within 3 months before the first dose of
study drug or plans to use any of these medical therapies at any time during the study

10. Has had extracorporeal shock wave therapy (ESWT) for correction of Peyronie's disease
within the 6-month period before screening or plans to have ESWT at any time during
the study

11. Has used any mechanical type device for correction of Peyronie's disease within the
2-week period before screening or plans to use any these devices at any time during
the study

12. Has used a mechanical device to induce a passive erection within the 2-week period
before screening or plans to use any of these devices at any time during the study

13. Has significant erectile dysfunction that has failed to respond to oral treatment with
phosphodiesterase type 5 (PDE5) inhibitors

14. Has a penile Duplex Doppler ultrasound evaluation at screening that shows compromised
penile hemodynamics that in the opinion of the investigator is clinically significant

15. Has uncontrolled hypertension, as determined by the investigator

16. Has a known recent history of stroke, bleeding, or other significant medical
condition, which in the investigator's opinion would make the subject unsuitable for
enrollment in the study

17. Is unwilling or unable to cooperate with the requirements of the study including
completion of all scheduled study visits

18. Has received an investigational drug or treatment within 30 days before the first dose
of study drug

19. Has a known systemic allergy to collagenase or any other excipient of AA4500

20. Has a known allergy to any concomitant medication required as per the protocol

21. Has received anticoagulant medication (except for = 165 mg aspirin daily or = 800 mg
of over-the-counter NSAIDS daily) during the 7 days before each dose of study drug

22. Has received any collagenase treatments within 30 days of the first dose of study drug

23. Has, at any time, received AA4500 for the treatment of Peyronie's disease -

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s


The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
1/10/2010
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
1/03/2012
Sample size
Target
Accrual to date
Final
418
Recruitment in Australia
Recruitment state(s)
NSW,QLD,VIC,WA
Recruitment hospital [1] 0 0
Urology Sydney - Kogarah
Recruitment hospital [2] 0 0
Health Pac Medical Centre - Sydney
Recruitment hospital [3] 0 0
AusTrials Pty Limited - Brisbane
Recruitment hospital [4] 0 0
Bayside Urology - Mentone
Recruitment hospital [5] 0 0
Keogh Institute for Medical Research - Nedlands
Recruitment postcode(s) [1] 0 0
NSW 2217 - Kogarah
Recruitment postcode(s) [2] 0 0
NSW 2000 - Sydney
Recruitment postcode(s) [3] 0 0
QLD 4000 - Brisbane
Recruitment postcode(s) [4] 0 0
VIC 3193 - Mentone
Recruitment postcode(s) [5] 0 0
WA 6009 - Nedlands
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Alabama
Country [2] 0 0
United States of America
State/province [2] 0 0
Alaska
Country [3] 0 0
United States of America
State/province [3] 0 0
Arizona
Country [4] 0 0
United States of America
State/province [4] 0 0
California
Country [5] 0 0
United States of America
State/province [5] 0 0
Colorado
Country [6] 0 0
United States of America
State/province [6] 0 0
Connecticut
Country [7] 0 0
United States of America
State/province [7] 0 0
Florida
Country [8] 0 0
United States of America
State/province [8] 0 0
Idaho
Country [9] 0 0
United States of America
State/province [9] 0 0
Indiana
Country [10] 0 0
United States of America
State/province [10] 0 0
Kansas
Country [11] 0 0
United States of America
State/province [11] 0 0
Louisiana
Country [12] 0 0
United States of America
State/province [12] 0 0
Maryland
Country [13] 0 0
United States of America
State/province [13] 0 0
Michigan
Country [14] 0 0
United States of America
State/province [14] 0 0
New Jersey
Country [15] 0 0
United States of America
State/province [15] 0 0
New York
Country [16] 0 0
United States of America
State/province [16] 0 0
North Carolina
Country [17] 0 0
United States of America
State/province [17] 0 0
Rhode Island
Country [18] 0 0
United States of America
State/province [18] 0 0
Texas

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Endo Pharmaceuticals
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
This study is a Phase 3, double-blind, randomized, placebo-controlled study of the safety and
efficacy of AA4500 0.58 mg in subjects with Peyronie's disease. Approximately 300 (200 AA4500
and 100 placebo) men will be randomized. Subjects will be screened for study eligibility
within 21 days before the initial injection of study drug in the first treatment cycle.

Before dosing, subjects will be stratified by degree of penile curvature (ie, 30º to 60º or
61º to 90º) and then randomized into two treatment groups to receive in a 2:1 ratio either
AA4500 0.58 mg or placebo.

In this study, qualified subjects may receive up to four treatment cycles; each cycle will be
separated by a period of 42 days (± 5 days). During each treatment cycle, subjects will
receive two injections of study drug with at least 24 hours but not more than 72 hours
between injections. After the final injection of each treatment cycle, the investigator or
qualified designee will model the penile plaque in an attempt to stretch or elongate the
plaque. If the subject's penile curvature is reduced to < 15 degrees after the first, second,
or third cycle of injections or if the investigator determines further treatment is not
clinically indicated (eg, adverse events; allergic reaction), subsequent treatment cycles
will not be administered.

Following the maximum of four treatment cycles, each subject will be followed for additional
safety and efficacy assessments on Days 169 (± 7 days), 232 (± 7 days), 295 (± 7 days), 365
(± 7 days) (nominal weeks 24, 33, 42 and 52). Subjects randomized to placebo may receive
open-label AA4500 treatment after completing this study as part of another protocol.
Trial website
https://clinicaltrials.gov/ct2/show/NCT01221623
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Gregory Kaufman, MD
Address 0 0
Auxilium Pharmaceuticals, Inc.
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT01221623